159 related articles for article (PubMed ID: 27514622)
1. Transthyretin Cardiac Amyloidosis: From Rare Monogenic Disease to Common Pathway in Heart Failure?
Culotta V; Moon JC
Rev Esp Cardiol (Engl Ed); 2016 Oct; 69(10):888-889. PubMed ID: 27514622
[No Abstract] [Full Text] [Related]
2. Cardiac Dysautonomia and Survival in Hereditary Transthyretin Amyloidosis.
Goldstein DS
JACC Cardiovasc Imaging; 2016 Dec; 9(12):1442-1445. PubMed ID: 27838301
[No Abstract] [Full Text] [Related]
3. Transthyretin Amyloidosis: A "Zebra" of Many Stripes.
Semigran MJ
J Am Coll Cardiol; 2016 Jul; 68(2):173-5. PubMed ID: 27386770
[No Abstract] [Full Text] [Related]
4. Recognition and Implications of Undiagnosed Cardiac Amyloid Patients in HFpEF Trials.
Cheng RK; Maurer MS
JACC Heart Fail; 2021 Nov; 9(11):803-806. PubMed ID: 34509407
[No Abstract] [Full Text] [Related]
5. "SGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series" comment.
Patoulias D; Papadopoulos C; Doumas M
Intern Emerg Med; 2022 Aug; 17(5):1553-1554. PubMed ID: 35334061
[No Abstract] [Full Text] [Related]
6. Amyloid transthyretin cardiac amyloidosis with different manifestations, test findings and types.
Budweg J; Al-Ani M; Assaf Y; Parker A; Aranda J
BMJ Case Rep; 2023 Apr; 16(4):. PubMed ID: 37080632
[TBL] [Abstract][Full Text] [Related]
7. Recognizing Transthyretin Cardiac Amyloidosis in Patients With Aortic Stenosis: Impact on Prognosis.
Sperry BW; Jones BM; Vranian MN; Hanna M; Jaber WA
JACC Cardiovasc Imaging; 2016 Jul; 9(7):904-906. PubMed ID: 27085437
[No Abstract] [Full Text] [Related]
8. Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report.
Yamamoto H; Hashimoto T; Kawamura S; Hiroe M; Yamashita T; Ando Y; Yokochi T
J Med Case Rep; 2018 Dec; 12(1):370. PubMed ID: 30553273
[TBL] [Abstract][Full Text] [Related]
9. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
Paton DM
Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
[TBL] [Abstract][Full Text] [Related]
10. The Truth Is Unfolding About Transthyretin Cardiac Amyloidosis.
Grodin JL; Maurer MS
Circulation; 2019 Jul; 140(1):27-30. PubMed ID: 31549879
[No Abstract] [Full Text] [Related]
11. Sporadic Cardiac Amyloidosis by Amyloidogenic Transthyretin V122I Variant.
Nehashi T; Oikawa M; Amami K; Kanno Y; Yokokawa T; Misaka T; Yamada S; Kunii H; Nakazato K; Ishida T; Takeishi Y
Int Heart J; 2019 Nov; 60(6):1441-1443. PubMed ID: 31666456
[TBL] [Abstract][Full Text] [Related]
12. Clinical and pathological studies of cardiac amyloidosis in transthyretin type familial amyloid polyneuropathy.
Hattori T; Takei Y; Koyama J; Nakazato M; Ikeda S
Amyloid; 2003 Dec; 10(4):229-39. PubMed ID: 14986482
[TBL] [Abstract][Full Text] [Related]
13. Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis.
Bistola V; Parissis J; Foukarakis E; Valsamaki PN; Anastasakis A; Koutsis G; Efthimiadis G; Kastritis E
Heart Fail Rev; 2021 Jul; 26(4):861-879. PubMed ID: 33452596
[TBL] [Abstract][Full Text] [Related]
14. Transthyretin Cardiac Amyloidosis Disguised as Light Chain Amyloidosis or Multiple Myeloma?
Stein AP; Matthia EL; Petty SA; Stewart B; Vilaro JR; Al-Ani MAZ; Ahmed MM; Aranda JM; Hiemenz JW; Parker AM
Am J Cardiol; 2024 Jan; 210():85-92. PubMed ID: 37852567
[TBL] [Abstract][Full Text] [Related]
15. Amyloid Cardiomyopathy in the Rare Transthyretin Tyr78Phe Mutation.
Tini G; Vianello PF; Gemelli C; Grandis M; Canepa M
J Cardiovasc Transl Res; 2019 Dec; 12(6):514-516. PubMed ID: 30604309
[TBL] [Abstract][Full Text] [Related]
16. Novel Cardiovascular Magnetic Resonance Model to Distinguish Immunoglobulin Light Chain From Transthyretin Cardiac Amyloidosis.
Slivnick JA; Tong MS; Nagaraja HN; Elamin MB; Wallner A; O'Brien A; Raman SV; Zareba KM
JACC Cardiovasc Imaging; 2021 Jan; 14(1):302-304. PubMed ID: 32950451
[No Abstract] [Full Text] [Related]
17. Beneficial Effect of Pimobendan for Severe Heart Failure Due to Transthyretin Cardiac Amyloidosis.
Okamoto N; Kubo T; Nakashima Y; Ochi Y; Takahashi A; Baba Y; Hirota T; Yamasaki N; Kitaoka H
Intern Med; 2020 Feb; 59(3):339-343. PubMed ID: 31588087
[TBL] [Abstract][Full Text] [Related]
18. How to Identify Transthyretin Cardiac Amyloidosis at an Early Stage.
Izumiya Y; Hayashi H; Ishikawa H; Shibata A; Yoshiyama M
Intern Med; 2021 Jan; 60(1):1-7. PubMed ID: 32713926
[TBL] [Abstract][Full Text] [Related]
19. Unmasking Early Wild-Type Transthyretin Amyloidosis Cardiomyopathy in a Patient With Refractory Atrial Fibrillation and Unremarkable Cardiac Imaging.
Varedi D; Kovacsovics T; Downs Kelly E; Abraham J; Cowley J; Barrell K; Revelo MP; Stehlik J; Drakos S; Marrouche N; Wilson B; Swanson EA; Fang J; Nativi-Nicolau J
Circ Heart Fail; 2018 Jul; 11(7):e004812. PubMed ID: 29921704
[No Abstract] [Full Text] [Related]
20. Early identification of transthyretin-related hereditary cardiac amyloidosis.
Arbustini E; Merlini G
JACC Cardiovasc Imaging; 2014 May; 7(5):511-4. PubMed ID: 24831211
[No Abstract] [Full Text] [Related]
[Next] [New Search]
